Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

celecoxib

  • Home
  • celecoxib
Celecoxib Cuts Opioid Use Nearly in Half After Throat Surgery—Without Increasing Pain
Posted innews Otorhinolaryngology

Celecoxib Cuts Opioid Use Nearly in Half After Throat Surgery—Without Increasing Pain

Posted by MedXY By MedXY 04/02/2026
A retrospective cohort study of 80 patients undergoing tonsillectomy, adenoidectomy, or uvulopalatopharyngoplasty found that adding celecoxib to multimodal analgesia reduced mean opioid consumption by 44%, while maintaining comparable pain control across postoperative days 1, 5, and 10.
Read More
Postoperative ctDNA Identifies Stage III Colon Cancer Patients Who May Benefit from Adjuvant Celecoxib
Posted inHematology-Oncology news Oncology

Postoperative ctDNA Identifies Stage III Colon Cancer Patients Who May Benefit from Adjuvant Celecoxib

Posted by MedXY By MedXY 12/07/2025
A post hoc analysis of CALGB (Alliance)/SWOG 80702 shows postoperative ctDNA positivity strongly predicts recurrence and suggests adjuvant celecoxib improves DFS and OS in ctDNA-positive stage III colon cancer.
Read More
  • Immune-Cell Transcriptomics and Mendelian Randomisation Identify New Causal Genes for Type 2 Diabetes Complications
  • Retatrutide Produces Broad Favorable Shifts in Fatty Acid Oxidation and Insulin Resistance Biomarkers in Obesity With or Without Type 2 Diabetes
  • Improving the Algorithm: Adding a Socioeconomic Measure to Predict Type 2 Diabetes in Youth With Prediabetes
  • Safety of Biopsy in Pheochromocytoma and Paraganglioma: What a Global Study Found
  • Heart Failure Medication Adherence Depends Less on Motivation Than on Whether Treatment Fits Daily Life
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in